Skip to content

Net Change in Cash at other companies

Opko Health logo
Opko HealthOPK
-$27.18M-769%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$33.19M+834%
AMP
Amphastar PharmaceuticalsAMPH
$762K-97.6%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$120.3M+65.2%
HRO
HarrowHROW
$21.72M+11.5%
Precigen logo
PrecigenPGEN
-$22.75M+3.0%

Other financials

Income statement

See full
Revenue$58.3M+104%
Gross profit$46.3M+86.8%
Operating income-$15.5M+80.4%
Net income-$30.4M+67.8%
EPS (diluted)-$0.37+71.8%

Balance sheet

See full
Cash & equivalents$180.9M-14.8%
Total debt$166.3M-18.3%
Total equity-$337.0M+0.4%
Total assets$305.1M+3.7%

Cash flow

See full
Operating cash flow-$15.6M+81.6%
CapEx$61.0K+239%
Free cash flow-$15.7M+81.5%

Valuation

See full
Market cap$846.21M+13.4%
Enterprise value$831.61M+12.7%
P/S4.1×-5.0×

Profitability

See full
Gross margin84.9%-1.3pp
Operating margin-47.1%-21.9pp
Net margin-76.8%-34.5pp
FCF margin-47.7%-22.1pp

Returns & leverage

See full
Return on equity-147.9%
Debt / equity5.6×
Current ratio2.2×-1.4×

Where this comes from

Reported directly by Phathom Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The official record: Phathom Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Phathom Pharmaceuticals, Inc.'s net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Phathom Pharmaceuticals, Inc.'s net change in cash?
Phathom Pharmaceuticals, Inc. (PHAT) reported net change in cash of $50.93M in Q1 2026.
How has Phathom Pharmaceuticals, Inc.'s net change in cash changed year-over-year?
Phathom Pharmaceuticals, Inc.'s net change in cash increased by 160.0% year-over-year, from -$84.95M to $50.93M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.